Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

BACKGROUND: Bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) is guideline-recommended treatment for human immunodeficiency virus type 1 (HIV-1). We evaluated whether people receiving dolutegravir (DTG) plus F/TAF or F/TDF (tenofovir disoproxil fumarate) with viral suppression can switch...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Infect Dis
Autors principals: Sax, Paul E, Rockstroh, Jürgen K, Luetkemeyer, Anne F, Yazdanpanah, Yazdan, Ward, Douglas, Trottier, Benoit, Rieger, Armin, Liu, Hui, Acosta, Rima, Collins, Sean E, Brainard, Diana M, Martin, Hal
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Online Only Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282313/
https://ncbi.nlm.nih.gov/pubmed/32668455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa988
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars